Abstract Categories

Track A BASIC SCIENCE

Basic Retrovirology
A1 HIV-1: Attachment, penetration and tropism
A2 HIV-1: Reverse transcription
A3 HIV-1: Integration
A4 HIV-1: Regulation of HIV transcription
A5 HIV-1: Viral maturation and assembly
A6 HIV-1: Regulatory and accessory gene functions and proteins
A7 HIV-1: Viral dynamics
A8 HIV-1: Variability
A9 HIV-2
A10 Other human retroviruses
A11 Animal lentiviruses

Diagnosis
A12 Diagnostics – Immunological
A13 Diagnostics – Molecular (e.g. viral load measurements)
A14 Diagnostics – DNA-based methods
A15 Diagnostics – other

Animal Models
A16 Animal Models – Pathogenesis
A17 Animal Models – Treatment
A18 Animal models – Vaccines

Immunology and Pathogenesis
A19 Virus-specific humoral immunity
A20 Virus-specific cellular immunity
A21 HIV induced abnormalities of humoral immunity
A22 HIV induced abnormalities of cellular immunity
A23 HIV pathogenesis – in vivo
A24 HIV pathogenesis – in vitro
A25 Apoptosis
A26 Cytokines
A27 Vaccines

Treatment
A28 Antivirals
A29 Resistance
A30 Immunotherapy
A31 Gene therapy

Opportunistic Pathogens
A32 HHV-8
A33 Other herpesviruses
A34 Bacteria and mycobacteria
A35 Fungi
A36 Protozoa and other pathogens
A37 Basic science: Policy and Ethics

Track B CLINICAL SCIENCE and care

Course of Infection and Disease
B1 Role of cofactors in disease development
B2 Prognostic staging of disease
B3 Clinical heterogeneity among geographic regions
B4 Perinatal infections
B5 Paediatric disease
B6 Primary (initial) infection

HIV-related Diseases
B7 Bacterial
B8 Tuberculosis
B9 Mycobacteria other than tuberculosis
B10 Pneumocystis carinii
B11 Sexually transmitted diseases
B12 Fungal
B13 Protozoal
B14 Viral
B15 Kaposi’s sarcoma
B16 Lymphoma
B17 Cervical dysplasia and STD-related neoplasia
B18 Other HIV-related diseases

Organ Systems
B19 Gastrointestinal
B20 Genitourinary
B21 Gynaecological
B22 Hematological, immunological
B23 Metabolic/Wasting
B24 Nervous system
B25 Obstetrical
B26 Ophthalmological
B27 Oral
B28 Psychiatric
B29 Pulmonary
B30 Dermatological
B31 Other organ systems (e.g. allergy, rheumatology)

Antiretroviral Therapies
B32 Clinical trials – phase I/II
B33 Clinical trials – phase III/post-licensing
B34 Clinical trials – paediatric
B35 Protease Inhibitors
B36 Nucleoside Reverse Transcriptase Inhibitors
B37 Non-nucleoside RTIs
B38 Other targets
B39 Combination therapy
B40 Viral resistance
B41 Pharmacology & Pharmacokinetics
B42 Drug interactions / adverse reactions
B43 Initiation of therapy
B44 Adherence / Compliance
B45 Access to therapy / Strategies for delivery

Other HIV Therapies
B46 Immunotherapies (including cytokines)
B47 Gene Therapy
B48 Other therapies
B49 Nutrition
B50 Alternative, complementary and traditional medicines

Provision of Care
B51 Primary care and health maintenance
B52 Institutional care (inpatient/outpatient/day care)
B53 Palliative care / End of life
B54 Home care (including intravenous antibiotics)
B55 Nursing
B56 Holistic care
B57 Specific populations (e.g. injecting drug users, adolescents, prisoners, etc.)
B58 Paediatrics
B59 Care in resource-limited settings
B60 Patient perspective of clinical disease & care

Methodological Issues
B61 Diagnosis of HIV infection (antibody and virus detection)
B62 Viral load
B63 Other markers of disease progression
B64 Measurement of viral resistance
B65 Design, implementation and evaluation of clinical trials
B66 Quality of care
B67 Ethical issues (care/trials)
B68 Licensing and regulatory issues
B69 Treatments activism and education
B70 Clinical trials – involvement of people with HIV and AIDS
B71 Clinical science: Policy and Ethics

Track C EPIDEMIOLOGY, prevention & PUBLIC HEALTH

Epidemiology
C1 Descriptive and molecular epidemiology – global
C2 Descriptive and molecular epidemiology – Africa
C3 Descriptive and molecular epidemiology – Asia & Oceania
C4 Descriptive and molecular epidemiology – Latin America & the Caribbean
C5 Descriptive and molecular epidemiology – Europe
C6 Descriptive and molecular epidemiology – North America
C7 Demographic co-factors

Associated Epidemics
C8 Opportunistic illnesses
C9 Tuberculosis – HIV interactions
C10 STD – HIV interactions
C11 HIV-2
C12 Other pathogens

Natural History, Progression and Survival
C13 Cofactors in disease progression, biological
C14 Cofactors in disease progression, socioeconomic & behavioural
C15 Long term survivors
C16 Infants and children
C17 Specific populations (e.g. women, haemophiliacs, adolescents, etc.)

HIV Transmission and Risk Factors
C18 Between men
C19 Between men and women
C20 Injection drug users
C21 Blood/blood product recipients
C22 Perinatal transmission
C23 Occupational transmission
C24 Factors associated with transmission (STDs, age, circumcision, etc.)
C25 Viral load and transmission
C26 Sexual practices
C27 Women
C28 Special populations (e.g. prisoners, sex workers)

Prevention Interventions: Biological & Technological
C29 Male condoms
C30 Female condoms / female controlled methods
C31 Microbicides
C32 Antivirals
C33 Post-exposure prophylaxis
C34 Safer injecting equipment
C35 Blood and blood product safety
C36 Vaccines
C37 STD diagnosis and treatment
C38 Other

Prevention Interventions: Behavioural and Societal
C39 Counselling
C40 Outreach
C41 Harm reduction
C42 Social marketing
C43 Media and communication
C44 Peer education
C45 Testing
C46 Community development
C47 Legal contexts
C48 Political and structural development
C49 Specific populations (e.g. people living with HIV & AIDS, sex workers, gay men)

Settings for Prevention
C50 Community sites
C51 Workplace
C52 Health care settings
C53 Schools
C54 Military
C55 Incarcerated/institutionalised populations
C56 Reproductive health
C57 Other

Methodological issues
C58 Reporting systems, surveillance of HIV and AIDS
C59 Modeling, back calculation forecasting, impact analysis, scenario analysis
C60 Programme planning and management
C61 Design, implementation & evaluation of vaccine / microbicide trials
C62 Epidemiology, Prevention & Public Health: Policy and Ethics

Track D SOCIAL AND BEHAVIOURAL SCIENCE

Behavioural Science
D1 Measurement of behaviour
D2 Determinants of behaviour, social
D3 Determinants of behaviour, economic
D4 Determinants of behaviour, cultural
D5 Evaluation of behavioural interventions
D6 Behavioural research methods
D7 Human sexuality
D8 Quality of life assessment

Social Sciences
D9 Anthropology, Ethnology
D10 Demography
D11 Development studies
D12 Economics
D13 Political science
D14 Political and social history, political economy
D15 Psychology, neuropsychology
D16 Sociology
D17 Methodological issues in social & behavioural science

Demographic Impact
D18 Mortality
D19 Fertility
D20 Household & family structure, orphans

Psychological Impact & Response
D21 Mental health
D22 Death and dying
D23 Life and living, improved survival
D24 Political and Economic Impact & Response
D25 Stress & coping (providers, family, & peers)
D26 Counselling
D27 Group work (e.g. support groups, peer groups)

Social Impact & Response
D28 Impact & response, community
D29 Impact & response, cultural & religious
D30 Impact & response, media
D31 Social support programmes
D32 Self-help organisations
D33 AIDS service organisations
D34 National and international networks

Law, Legislation, Ethics & Human Rights
D35 Law & legislation
D36 Ethics
D37 Human rights
D38 Discrimination, stigmatisation
D39 Privacy, confidentiality, duty to warn
D40 Prisons and institutions

Special populations (e.g. refugees, immigrants, sex workers)
D41 Macroeconomic impact
D42 Sectoral impact
D43 Household & family impact
D44 Private sector response
D45 Poverty alleviation
D46 Resource mobilization, fund-raising
D47 Policy determinants & constraints (e.g. cultural, economic, political)
D48 Resource allocation (e.g. cost-effectiveness and decision analysis)
D49 Influencing policy (e.g. activism, advocacy, community mobilization, public relations)
D50 Programme evaluation

[Main Page] [Email Us] [Join our List ] [Registration ]

© The 12th World AIDS Conference,1997. All rights reserved.
Text and images on this page may be reproduced for non-commercial purposes only.